⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNLI News
Denali Therapeutics Inc. Common Stock
Form 8-K
sec.gov
DNLI
Form 8-K
sec.gov
DNLI
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
globenewswire.com
DNLI
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
prnewswire.com
PRME
IOVA
MDGL
DNLI
Form 8-K
sec.gov
DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
globenewswire.com
DNLI
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
globenewswire.com
WVE
ALNY
DNLI
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
globenewswire.com
DNLI
ISPE Announces 2026 Facility of the Year Awards (FOYA) Submission Finalists at the 2026 ISPE Facilities of the Future Conference
prnewswire.com
AZN
DNLI
LLY
JNJ
MRK
MRNA
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
globenewswire.com
DNLI